JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. Full abstract: https://t.co/ViK5wjifW
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. Full abstract: https://t.co/CewzuUBWz
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. Full abstract: https://t.co/4uzijXERs
CAR-T療法ってすごいな〜🙌 日本でも保険収載される日がくるのだろうか。 https://t.co/H4alYVlVA4
RT @DrRaulCordoba: #Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell #Lymphoma | @NEJM #CARTcell #tcellrx #ImmunoOnc…
RT @ixazebe: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/45m8N0BJcC
RT @Olguitxi: Sumando evidencias con medicamentos CAR-T ya disponibles https://t.co/fF8Uf1qdpR
Fascinating results. Very exciting! Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/eYHn2OBqSg
RT @ixazebe: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/45m8N0BJcC
Juliet for R/R DLBCL https://t.co/PojhD2UkX0
RT @gloria_iacoboni: One more NEJM for CAR-T cell therapy. Congratulations to the JULIET investigators, looking forward to reproducing thes…
RT @Olguitxi: Sumando evidencias con medicamentos CAR-T ya disponibles https://t.co/fF8Uf1qdpR
RT @Olguitxi: Sumando evidencias con medicamentos CAR-T ya disponibles https://t.co/fF8Uf1qdpR
One more NEJM for CAR-T cell therapy. Congratulations to the JULIET investigators, looking forward to reproducing these results in real-life patients.
RT @MediHumdani: Absolutely terrible way of describing efficacy "At 12 months ***after the initial response***, the rate of relapse-free su…
RT @MediHumdani: Absolutely terrible way of describing efficacy "At 12 months ***after the initial response***, the rate of relapse-free su…
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/45m8N0BJcC
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma - clinical response seen across the board. https://t.co/0ZeKFmNcwT https://t.co/oOAgJuyoam
Sumando evidencias con medicamentos CAR-T ya disponibles https://t.co/fF8Uf1qdpR
CAR T-cell therapy in relapsed/refractory DLBCL lead to high rates of durable responses with the use of tisagenlecleucel @nejm Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/E6FNCiWkBv
RT @MediHumdani: Absolutely terrible way of describing efficacy "At 12 months ***after the initial response***, the rate of relapse-free su…
RT @paselsab: Otro mas para ono-hemato https://t.co/detxVRXzGt
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/lYjeupNaHO
RT @DrRaulCordoba: #Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell #Lymphoma | @NEJM #CARTcell #tcellrx #ImmunoOnc…
RT @MediHumdani: Absolutely terrible way of describing efficacy "At 12 months ***after the initial response***, the rate of relapse-free su…
RT @MediHumdani: Absolutely terrible way of describing efficacy "At 12 months ***after the initial response***, the rate of relapse-free su…
RT @MediHumdani: Absolutely terrible way of describing efficacy "At 12 months ***after the initial response***, the rate of relapse-free su…
RT @DrRaulCordoba: #Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell #Lymphoma | @NEJM #CARTcell #tcellrx #ImmunoOnc…
#Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell #Lymphoma | @NEJM #CARTcell #tcellrx #ImmunoOnc #lymsm https://t.co/1EMX63QPER
Otro mas para ono-hemato https://t.co/detxVRXzGt
RT @MediHumdani: Absolutely terrible way of describing efficacy "At 12 months ***after the initial response***, the rate of relapse-free su…
RT @MediHumdani: Absolutely terrible way of describing efficacy "At 12 months ***after the initial response***, the rate of relapse-free su…
RT @MediHumdani: Absolutely terrible way of describing efficacy "At 12 months ***after the initial response***, the rate of relapse-free su…
RT @MediHumdani: Absolutely terrible way of describing efficacy "At 12 months ***after the initial response***, the rate of relapse-free su…
RT @MediHumdani: Absolutely terrible way of describing efficacy "At 12 months ***after the initial response***, the rate of relapse-free su…
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/0vRX19gyth
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/mc5DVKUEXZ
RT @marrowonthemove: 🚗 Ready to learn more about CAR-T cells for #lymphoma? 🚗Our very own Dr. Veronika Bachanova contributed to this landma…
RT @marrowonthemove: 🚗 Ready to learn more about CAR-T cells for #lymphoma? 🚗Our very own Dr. Veronika Bachanova contributed to this landma…
RT @marrowonthemove: 🚗 Ready to learn more about CAR-T cells for #lymphoma? 🚗Our very own Dr. Veronika Bachanova contributed to this landma…
RT @UMN_DOMResearch: Great work, Dr. Bachanova!! https://t.co/JSPJ7kn0Au
RT @marrowonthemove: 🚗 Ready to learn more about CAR-T cells for #lymphoma? 🚗Our very own Dr. Veronika Bachanova contributed to this landma…
RT @UMN_DOMResearch: Great work, Dr. Bachanova!! https://t.co/JSPJ7kn0Au
Great work, Dr. Bachanova!!
🚗 Ready to learn more about CAR-T cells for #lymphoma? 🚗Our very own Dr. Veronika Bachanova contributed to this landmark study (JULIET trial) recently published in the New England Journal of Medicine! ⚕️ | https://t.co/R1VbQXN6tr @UMNresearch @UMNCancer @U
Kymriah (tisagenlecleucel) and JULIET, a story of DLBCL: Results of the international JULIET study published in @NEJM show durable responses of CD19-directed CAR-T cell therapy in DLBCL. Article: https://t.co/8aSH1M3S45; pubmed: https://t.co/iArEeAicqq. ht
RT @GENESIS_SEFH: Estudio JULIET: #Tisagenlecleucel en linfoma difuso de células B grandes recidivante o refractario en adultos. Tasa de re…
Estudio JULIET: #Tisagenlecleucel en linfoma difuso de células B grandes recidivante o refractario en adultos. Tasa de respuesta global 52% (IC95% 41 a 62): 40% respuesta completa y 12% respuesta parcial https://t.co/FqDslpjAcD https://t.co/DmZtBoYpHj
RT @HallekMichael: Very important data. Wish to see a bit longer follow up. But practice-changing without question. https://t.co/zupweAKzUS
RT @NEJM: #ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regi…
RT @NEJM: #ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regi…
RT @SCTNB: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/QKVDn17S1H
RT @Florent_Malard: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma #lymphoma #DLBCLsm #ASH18 https://t.co/N…
Very important data. Wish to see a bit longer follow up. But practice-changing without question.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma #lymphoma #DLBCLsm #ASH18 https://t.co/NBy6j6LkZY
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/FmdBFogPwX
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/QKVDn17S1H
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/spBHoFlk8G
#Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell #Lymphoma #ASH18 #ssbmt #lymsm https://t.co/oiSBOMqHqy
#NEJM #novartis #tisagenlecleucel L'administration du traitement CAR-T tisagenlecleucel a produit des réponses durables chez des patients adultes atteints de lymphome diffus à grandes cellules B récidivant ou réfractaire.
RT @chadinabhan: JULIET trial @NEJM published. 165 enrolled and 111 infused. ORR 52% (if using 111) but 34% using ITT (165 pts); how best t…
Thus with a tis | TBL: One-third of patients planned for CAR-T cells for refractory DLBCL respond, and two-thirds of responders are estimated to remain disease-free at 12 months. https://t.co/ifHuAKrjil Do these big results @ #ASH18 leave you team Kymria
ICYMI: Results of the JULIET trial published in @NEJM #Immunotherapy #CARTcell
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @NEJM: #ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regi…
RT @NEJM: #ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regi…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @DrMiguelPerales: Reporting infused CAR T cell closer comparison to ZUMA-1 reporting. That is if we can compare nonrandomized trials 😉 #…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @doctorpemm: #ASH18 | #Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | @NEJM | #leusm #lysm #ImmunoOn…
RT @gonen_mithat: An example of immortal time bias? If you are a complete responder you must have a lived a minimum amount of time which ex…
New England Journal of HEMATOLOGY
RT @DrMiguelPerales: Reporting infused CAR T cell closer comparison to ZUMA-1 reporting. That is if we can compare nonrandomized trials 😉 #…
RT @NEJM: #ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regi…
RT @chadinabhan: JULIET trial @NEJM published. 165 enrolled and 111 infused. ORR 52% (if using 111) but 34% using ITT (165 pts); how best t…
Reporting infused CAR T cell closer comparison to ZUMA-1 reporting. That is if we can compare nonrandomized trials 😉 #ash18 #CARTcells
RT @VincentScocuzza: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/CVcVJ6mRNu #ash18
RT @chadinabhan: JULIET trial @NEJM published. 165 enrolled and 111 infused. ORR 52% (if using 111) but 34% using ITT (165 pts); how best t…
RT @VincentScocuzza: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/CVcVJ6mRNu #ash18
RT @NEJM: #ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regi…
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/CVcVJ6mRNu #ash18
JULIET trial @NEJM published. 165 enrolled and 111 infused. ORR 52% (if using 111) but 34% using ITT (165 pts); how best to calculate? @Lymphoma_Doc @JohnPLeonardMD @DrMatasar @timfenske @StefanoLuminari @DrJFriedberg @jonathonbcohen https://t.co/3hOAANYL
RT @NEJM: #ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regi…